Harmony Biosciences Holdings (HRMY) EBITDA Margin Growth (3y) (2023 - 2026)

Harmony Biosciences Holdings (HRMY) EBITDA Margin Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 9,942.00
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 530.00
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -1,211.00
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -623.00
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Harmony Biosciences Holdings 2.07 Bn 1.55 Bn 170.88 Mn -1,662.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -1,662.00
Dec 31, 2025 -2,129.00
Sep 30, 2025 1,719.00
Jun 30, 2025 -691.00
Mar 31, 2025 -185.00
Dec 31, 2024 -370.00
Sep 30, 2024 709.00
Jun 30, 2024 -1,922.00
Mar 31, 2024 930.00
Dec 31, 2023 1,008.00
Sep 30, 2023 1,749.00
Jun 30, 2023 1,571.00
Mar 31, 2023 8,237.00